Hua Er Jie Jian Wen·2025-08-29 10:23Core Transaction Details - The license target is the subsidiary Fosun Pharma, which has obtained exclusive rights for the development, production, registration, and commercialization of the AC-201 molecule and its drugs in mainland China and Hong Kong and Macau [1] - The licensor is Aikeno Biopharmaceuticals (Suzhou) Co., Ltd. [1] - The licensing field is for the diagnosis, prevention, and treatment of human diseases [1] Product Information - AC-201 is an oral small molecule JAK inhibitor primarily used for autoimmune diseases [1] - Clinical progress includes the completion of Phase II clinical trials for the first indication (moderate to severe plaque psoriasis), with positive data indicating good safety and tolerability [1] - The market size for JAK inhibitors is projected to reach approximately $16.8 billion in global sales by 2024 [1] Payment Arrangement - The total payment amount is up to 156 million yuan (including an upfront payment of 60 million yuan and milestone payments of up to 96 million yuan) [1] - Sales commissions will be paid based on a predetermined percentage of annual net sales [1] - Milestone payments will be made based on the achievement of annual net sales targets [1]